Literature DB >> 17898229

Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.

Robert S Bitner1, William H Bunnelle, David J Anderson, Clark A Briggs, Jerry Buccafusco, Peter Curzon, Michael W Decker, Jennifer M Frost, Jens Halvard Gronlien, Earl Gubbins, Jinhe Li, John Malysz, Stella Markosyan, Kennan Marsh, Michael D Meyer, Arthur L Nikkel, Richard J Radek, Holly M Robb, Daniel Timmermann, James P Sullivan, Murali Gopalakrishnan.   

Abstract

The alpha7 nicotinic acetylcholine receptor (nAChR) plays an important role in cognitive processes and may represent a drug target for treating cognitive deficits in neurodegenerative and psychiatric disorders. In the present study, we used a novel alpha7 nAChR-selective agonist, 2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole (A-582941) to interrogate cognitive efficacy, as well as examine potential cellular mechanisms of cognition. Exhibiting high affinity to native rat (Ki = 10.8 nM) and human (Ki = 16.7 nM) alpha7 nAChRs, A-582941 enhanced cognitive performance in behavioral assays including the monkey delayed matching-to-sample, rat social recognition, and mouse inhibitory avoidance models that capture domains of working memory, short-term recognition memory, and long-term memory consolidation, respectively. In addition, A-582941 normalized sensory gating deficits induced by the alpha7 nAChR antagonist methyllycaconitine in rats, and in DBA/2 mice that exhibit a natural sensory gating deficit. Examination of signaling pathways known to be involved in cognitive function revealed that alpha7 nAChR agonism increased extracellular-signal regulated kinase 1/2 (ERK1/2) phosphorylation in PC12 cells. Furthermore, increases in ERK1/2 and cAMP response element-binding protein (CREB) phosphorylation were observed in mouse cingulate cortex and/or hippocampus after acute A-582941 administration producing plasma concentrations in the range of alpha7 binding affinities and behavioral efficacious doses. The MEK inhibitor SL327 completely blocked alpha7 agonist-evoked ERK1/2 phosphorylation. Our results demonstrate that alpha7 nAChR agonism can lead to broad-spectrum efficacy in animal models at doses that enhance ERK1/2 and CREB phosphorylation/activation and may represent a mechanism that offers potential to improve cognitive deficits associated with neurodegenerative and psychiatric diseases, such as Alzheimer's disease and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898229      PMCID: PMC6673141          DOI: 10.1523/JNEUROSCI.2444-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  78 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Role of alpha7 nicotinic acetylcholine receptor in calcium signaling induced by prion protein interaction with stress-inducible protein 1.

Authors:  Flavio H Beraldo; Camila P Arantes; Tiago G Santos; Nicolle G T Queiroz; Kirk Young; R Jane Rylett; Regina P Markus; Marco A M Prado; Vilma R Martins
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

Review 4.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

5.  L-3-n-butylphthalide Rescues Hippocampal Synaptic Failure and Attenuates Neuropathology in Aged APP/PS1 Mouse Model of Alzheimer's Disease.

Authors:  Yu Zhang; Long-Jian Huang; Si Shi; Shao-Feng Xu; Xiao-Liang Wang; Ying Peng
Journal:  CNS Neurosci Ther       Date:  2016-07-20       Impact factor: 5.243

6.  Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor.

Authors:  A Potasiewicz; T Kos; F Ravazzini; G Puia; H R Arias; P Popik; A Nikiforuk
Journal:  Br J Pharmacol       Date:  2015-10-10       Impact factor: 8.739

7.  Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases.

Authors:  C E Adams; J C Yonchek; K M Schulz; S L Graw; J Stitzel; P U Teschke; K E Stevens
Journal:  Neuroscience       Date:  2012-01-25       Impact factor: 3.590

8.  Presynaptic α7 nicotinic acetylcholine receptors enhance hippocampal mossy fiber glutamatergic transmission via PKA activation.

Authors:  Qing Cheng; Jerrel L Yakel
Journal:  J Neurosci       Date:  2014-01-01       Impact factor: 6.167

9.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

10.  Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons.

Authors:  Min Hu; Murali Gopalakrishnan; Jinhe Li
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.